retatrutide 20mg peptide Retatrutide-RUO Retatrutide 20mg Vial | Futureproof

Tirzepatide starts to lower blood sugar levels shortly after starting treatment, with maximum effects typically seen after several weeks of consistent use

Drumm C, Clowry J, Healy ML, Wynne B

GLP-1 Market Size: USD 68.65 billion in 2026 | USD 195.01 billion by 2035 | CAGR: 12.3% | Leading Molecule: Semaglutide ( 52.1% revenue share) | Dominant Region: United States ( 62.8% revenue share) GLP-1 Weight Loss Drug Market Highlights: Key Data at a Glance ( 2026 ) GLP-1 Weight Loss Drug Market Size 2026 : USD 68.65 billion , forecast USD 195.01 billion by 2035 at 12.3% CAGR Dominant drug class: Dual GIP/GLP-1 Agonists (tirzepatide) and Injectable GLP-1 RA Monoagonists (semaglutide) with 78.4% combined revenue share Fastest-growing route: Oral GLP-1 formulations at 34.2% CAGR through 2035 driven by injection-free patient access expansion GLP-1 market leaders: Novo Nordisk and Eli Lilly with approximately 87% combined prescription weight management drug revenue share in 2026 Most prescribed weight loss molecule: Semaglutide (Wegovy and Ozempic) with 52.1% global GLP-1 market revenue share in 2026 FDA-approved anti-obesity GLP-1 drugs: Four molecules including semaglutide, tirzepatide, liraglutide, and oral semaglutide as of 2026 Global obesity patient pool: More than 1.1 billion adults with obesity globally

Michael Buontempo, a resident physician at Dartmouth-Hitchcock Medical Center, explains: Most hair shedding on GLP-1s looks like androgenetic alopecia unmasked by an episode of telogen effluvium driven by the magnitude of weight loss, rather than a direct drug toxicity. This means some people discover they have genetic hair loss when the telogen effluvium pulls away enough hair to reveal the underlying pattern

In practical terms: Tirzepatide offers well-documented, steady metabolic support and weight-loss results